Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | Blinatumomab for R/R Ph+ AML

Giovanni Martinelli • 25 Oct 2019
COSTEM 2019
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab

Giovanni Martinelli, MD, University in Bologna, Bologna, Italy, elaborates on his study regarding blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (R/R Ph+ ALL). This interview was recorded at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Giovanni Martinelli

CAR-T updates in AML and ALL
1:42
CAR-T updates in AML and ALL
Giovanni Martinelli • 7 Dec 2019
Gilteritinib for FLT+ R/R AML
1:20
Gilteritinib for FLT+ R/R AML
Giovanni Martinelli • 26 Oct 2019
Giovanni Martinelli: exciting CAR-T research
1:01
Giovanni Martinelli: exciting CAR-T research
Giovanni Martinelli • 25 Oct 2019
How will we pave the way to transplant for high risk patients?
1:12
How will we pave the way to transplant for high risk patients?
Giovanni Martinelli • 25 Oct 2019

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals